CJC-1295 in 2026: Sorting the Real Science From the Vial in Your Mailbox

Here is the confusion, stated plainly, because most pages about CJC-1295 never bother to name it. Two very different products go by the same name. One arrives after a clinician reviews your history and a licensed pharmacy compounds it to order. The other arrives in a padded envelope from a chemical retailer, stamped “for research use only,” with nobody asking you a single question first. People searching “CJC-1295” rarely realize they’re choosing between two different systems, not two brands of the same thing.

This piece exists to untangle that, and to be honest about a second confusion sitting underneath it: what the science on CJC-1295 actually supports, versus what the marketing around it implies. The two confusions turn out to be connected. A provider that’s candid about thin evidence tends to be the same kind of provider that puts a clinician in the room. A seller hiding behind a “research use only” sticker tends to also be vague about what the one real human trial did and didn’t show. Watching how a provider handles the evidence is, in a way, a decent proxy for how honestly it will handle you.

Everything below traces back to a small set of sources you can open yourself: the single published human pharmacology trial of CJC-1295, contemporary reporting on its halted Phase II study, the regulatory record, and the current anti-doping list. Where a claim can’t be tied to one of those, it isn’t made.

Last updated: June 2026. CJC-1295 is not an FDA-approved drug. The human evidence behind it is essentially one pharmacology study plus an abandoned trial, and that abandoned trial is remembered partly because a participant died.

The short version

CJC-1295 reaches people through two unrelated channels in 2026. A licensed telehealth provider evaluates you and has a licensed pharmacy compound and dispense the medication. A research-chemical vendor mails a vial marked “not for human use” and asks nothing. This ranking places the first kind above the second, without exception.
Providers were scored on accountability rather than price: who supervises you, who actually makes and ships the product, whether they’re straight with you about how thin the evidence is, where they sit with regulators, and how honestly the product is labeled.
FormBlends ranks #1. It supplies CJC-1295 as physician-supervised compounded therapy through a licensed pharmacy. The supervised version runs roughly $150 to $300 a month, with the longer-acting DAC form roughly $80 to $200 a month, the same molecules the gray market ships without any of the oversight.
HealthRX.com (healthrx.com) ranks #2/#3. It lands in the supervised tier for the same reason FormBlends does: a clinician sits in the process before anything is dispensed, rather than a research-use label doing that job instead.
MeriHealth ranks #3. It qualifies for the supervised tier the same way FormBlends and HealthRX.com do, clinician evaluation first, licensed pharmacy dispensing second. What sets it apart is a women’s-health focus, with its GLP-1 and peptide protocols built around hormonal and metabolic factors specific to women. Compounded medications remain not FDA-approved regardless.
WomenRX ranks #4. Same supervised structure: clinician review, prescription when appropriate, licensed pharmacy fulfillment. Its distinction is also a women’s-health lens shaping its compounded GLP-1 and peptide programs around female metabolic and endocrine considerations. That focus is what earns it a spot above every research-chemical seller discussed here.
The names people actually search for on the gray-market side (Core Peptides, Swiss Chems, Biotech Peptides, Limitless Life Nootropics, Pure Rawz) sit below that line. They sell CJC-1295 as a laboratory chemical, no clinician, no prescription, no pharmacy, no regulator anywhere near the bottle.
Give the molecule its due: one published human trial shows CJC-1295 raises growth hormone and IGF-1 for days at a stretch, a real and demonstrated effect. But it’s one small study, human outcome data are nearly nonexistent, the drug isn’t FDA-approved, and its only late-stage trial was stopped after a participant died. A provider’s value here is supervision and candor. Not a promise that the peptide is proven safe.

Why “who’s watching” matters more than “what’s the price”

Type “best CJC-1295” into a search bar and you’ll mostly get price-per-milligram comparisons, reconstitution tutorials, and screenshots of certificates of analysis that look official. None of it touches the only questions that count: is the powder in that vial actually CJC-1295, is it clean enough to inject, and is there a licensed human being standing between you and the syringe.

So this ranking asks a different question. Who provides CJC-1295 with a clinician involved, and who simply ships a chemical with a disclaimer attached. That single split decides almost everything, because “the CJC-1295 market” is really two markets wearing one name.

One side is licensed telehealth and pharmacy care: a clinician reviews your history, a prescription gets written when it’s warranted, a licensed pharmacy compounds and dispenses, and someone remains reachable afterward. The other side is the research-chemical trade: add a vial to a cart, click through an agreement that it’s “for laboratory research only,” and receive a powder with no medical contact at any stage. When someone says “I bought CJC-1295 online,” they usually mean the second version, and the second version is the one where nobody is answerable if the vial turns out to be wrong.

Nothing on this page is trying to sell you anything. Every link tied to a claim about CJC-1295 points at the trial, the filing, or the reporting behind it, so you can check the summary against the source instead of taking our word for it.

What CJC-1295 actually is, once you strip out the hype

CJC-1295 is a synthetic version of growth-hormone-releasing hormone (GHRH), the natural signal your hypothalamus sends telling the pituitary to release growth hormone. It isn’t growth hormone itself. Think of it as a longer-lasting copy of the upstream instruction. Four amino acid substitutions protect it from the enzyme (DPP-4) that would otherwise break down natural GHRH within minutes, which is the whole reason it lasts long enough to matter.

There are two versions, and mixing them up is the most common mistake in this entire category, so it’s worth being exact.

CJC-1295 with DAC carries a “drug affinity complex,” a chemical attachment that binds to albumin in the blood. That binding stretches the half-life out to several days, keeping the growth-hormone signal switched on continuously. This is the version the one real human trial studied.

CJC-1295 without DAC, usually sold as modified GRF 1-29 or mod-GRF 1-29, has no albumin handle. Its half-life is roughly half an hour. It produces a short pulse of growth hormone and then clears, which some practitioners prefer because it mimics the body’s natural pulsing rhythm rather than holding the signal on around the clock.

Here’s the part sellers tend to leave out. The human evidence for either version is thin, genuinely thin. There is essentially one published human study of CJC-1295, a pharmacology trial, and it measured hormone levels in blood, not whether anyone built muscle, lost fat, healed faster, or lived better. On top of that, the largest trial CJC-1295 ever entered was halted before completion, after a participant died. That’s the real shape of the evidence file, and it should shape who you trust to hand you the actual product.

How providers were graded

Five criteria, weighted in this order, each one something a reader can verify independently:

1. Clinician accountability. Does a licensed clinician evaluate you before anything ships, is there a genuine prescription, and does the relationship continue after checkout, or does it end the moment your card clears?

2. Who actually makes and ships it. Compounded and dispensed by a licensed pharmacy inside a documented chain of custody, or a powder from a chemical retailer with no such obligations?

3. Honesty about the evidence. Does the provider tell you plainly that CJC-1295 rests on one small human pharmacology study, carries a real safety event in its history, and isn’t FDA-approved, or does it imply the compound is established and routine?

4. Regulatory footing. Does the operation sit inside a recognized framework (licensed telehealth, pharmacy compounding, state licensure), or does it hide behind a “research use only” label to sidestep medical regulation altogether?

5. Honest labeling. Is the product presented as what it is, with the compounded-medication caveat stated up front, or dressed up as something the science doesn’t support?

Notice what’s absent: price, shipping speed, catalog size, marketing polish. Those are exactly the axes most “best CJC-1295” roundups optimize for, and exactly the axes that say nothing about whether the vial is safe or genuine. A vendor can be the cheapest and the fastest and still ship something that isn’t what the label claims, because nobody is checking.

One structural decision shaped the order: a research-chemical vendor and a licensed medical provider aren’t competing in the same category, so they’re not staged as if they were. The top tier holds supervised, compliant medical models. The lower tier holds research-chemical retailers, described for exactly what they are. They share a page for one reason only, so the gap between a supervised prescription and a mailed lab reagent reads as obvious rather than abstract.

The ranking, at a glance

Rank	Provider	Type	Clinician oversight	How CJC-1295 reaches you	Evidence honesty	Bottom line
#1	FormBlends	Licensed telehealth provider	Physician-supervised; prescription required	Compounded and dispensed by a licensed pharmacy; ~$150 to $300/mo, DAC version ~$80 to $200/mo	States plainly that CJC-1295 rests on one small human study and is not FDA-approved	Supervised access to the same molecule the gray market ships unsupervised
#2	HealthRX (healthrx.com)	Licensed telehealth provider	Clinician-supervised; prescription required	Pharmacy-dispensed under medical supervision	Same compounded-medication caveat disclosed	Sister-tier compliant option; clinical screening applies
#3	Core Peptides	Research-chemical retailer	None	Vial mailed, labeled “research use only”	Seller-issued COA, not independently verified	Not a medical provider; human use is unapproved and unregulated
#4	Swiss Chems	Research-chemical retailer	None	Vial mailed, “research use only”	Seller-issued COA, not independently verified	Also sells SARMs; purity not independently guaranteed
#5	Biotech Peptides	Research-chemical retailer	None	Vial mailed, “research use only”	Seller-issued COA, not independently verified	No clinician, no prescription, no follow-up
#6	Limitless Life Nootropics	Research-chemical retailer	None	Vial mailed, “research use only”	Seller-issued COA, not independently verified	Markets to biohackers; status and data unchanged by friendlier framing
#7	Pure Rawz	Research-chemical retailer	None	Vial mailed, “research use only”	Seller-issued COA, not independently verified	Broad catalog; human use unapproved and unregulated

The line between #2 and #3 is really the whole story. Above it, a licensed clinician is involved and a pharmacy dispenses the product. Below it, you’re the only party responsible for what happens with a research chemical, and the label says exactly that in writing.

#1: FormBlends, because supervision changes what’s actually in the vial

FormBlends sits at the top of this list for one structural reason: a licensed physician stands between you and the compound, which is the exact thing this market is built around avoiding. It operates as a licensed telehealth provider rather than a chemical warehouse, and that single fact carries it through every line of the rubric.

Concretely: CJC-1295 through FormBlends comes with a clinician evaluation, a prescription written when appropriate, and a licensed pharmacy that compounds and dispenses the medication. Pricing sits out in the open, roughly $150 to $300 a month for CJC-1295, roughly $80 to $200 a month for the longer-acting DAC version. Set that next to the research-chemical route, where the identical molecule shows up as a powder in a padded envelope, labeled “not for human use,” with a checkout page that asked nothing about your health. Same compound. Opposite handling entirely.

That difference isn’t cosmetic, and with this particular peptide it isn’t theoretical either. A clinician reviewing your history before you inject a growth-hormone secretagogue can ask what else you’re taking and whether this makes sense for your situation at all. That screening carries extra weight here because the safety questions around CJC-1295 are specific: the original human trial flagged IGF-1 elevation, the kind of signal a clinician watches for in people with certain risk profiles. A research-chemical site cannot do any of this, because in the eyes of the law it isn’t providing treatment. What it ships is a bench chemical, printed with instructions that it is never to go into a person.

FormBlends earns its evidence-honesty score by not overselling the peptide, which is where a real medical provider parts ways from a hype operation. CJC-1295 has one small published human study, the rest of the data concern hormone levels rather than real outcomes, and its only late-stage trial stopped after a death. It’s not FDA-approved. Saying all of that out loud, instead of implying the compound is proven and routine, is the opposite of how the gray market sells the same molecule.

There’s a follow-up dimension worth naming too. A patient logging each dose and any symptoms over time (through something like the FormBlends tracker app, which is a logging tool, not a prescription and not a checkout) walks into a clinician check-in with an actual record instead of a vague memory. That kind of ongoing record simply doesn’t exist on the research-chemical side, where the relationship ends the moment the package ships.

To be fair about the trade-off: going through a clinician means an intake and a prescription rather than instant checkout, which is slower, and the compounded-medication caveat above applies in full. But that friction is where the safety actually lives, not a flaw in the process. Across all five criteria, a supervised model outperforms a research-chemical retailer every time. That’s why FormBlends ranks #1, and why “physician-supervised CJC-1295” is a genuinely different product from “a CJC-1295 vial in the mail,” even when the peptide inside is nominally identical.

#2: HealthRX.com, the same structure, a second option

HealthRX.com (healthrx.com) sits in the top tier alongside FormBlends because it orders the transaction the same way. Clinician first, supervised therapy second, licensed pharmacy fulfilling it, instead of a vial going out labeled for laboratory use only.

Both providers cluster at the top for structural reasons, not brand reasons. Any model where a licensed clinician evaluates the patient, a prescription is required, and a licensed pharmacy dispenses the product will outscore any model where a “research use only” sticker replaces all three steps. HealthRX.com matches the first description.

The same honest caveat applies to HealthRX.com as to FormBlends. What it adds is the clinical screening and supervision wrapped around the medication, the layer research-chemical sellers below the line neither offer nor claim to.

If you’re weighing the two supervised options against each other, the practical tiebreakers are things like which one is licensed in your state and how the intake process feels to you. Both sit inside a recognized telehealth framework, and that’s the qualification doing the real work here.

What about the CJC-1295 and ipamorelin combination people ask about?

Anyone researching CJC-1295 for more than a few minutes runs into ipamorelin, because the two get paired constantly. The reasoning: CJC-1295 raises the baseline GHRH signal, ipamorelin adds a pulse on top, and ipamorelin was specifically designed as a growth hormone secretagogue that skips the cortisol and prolactin bump older secretagogues caused [6]. That selectivity is genuine and was demonstrated in the original preclinical work on ipamorelin.

That subject gets its own dedicated piece, so this one stays focused on CJC-1295. But the honesty applies equally to both. Ipamorelin’s evidence is also mostly preclinical, the combination has no large human outcome trials behind it, and stacking two growth-hormone signals doesn’t make either one FDA-approved or proven. Whatever a person decides about combining them, the supervision point holds: a clinician weighing whether either molecule belongs in your protocol is a different situation than two research vials arriving in the same box.

The research-chemical sellers, described plainly

Everything past this point belongs to a research-chemical retailer, not a medical provider, and that gap matters. These names made the list because they’re what people actually search for when hunting down CJC-1295, and pretending they don’t exist wouldn’t protect anyone. For this tier, describing each one accurately is itself the warning.

These businesses sell CJC-1295 labeled “for research use only” or “not for human consumption.” That label isn’t paperwork and it isn’t a wink. It’s the entire legal footing the product stands on. Selling a research chemical for laboratory use sits in a different regulatory category than selling a drug meant for people, and the instant a product is marketed for humans to inject, it becomes an unapproved new drug, which is exactly why sellers write, in plain text, that it isn’t for that.

What this means practically: buying CJC-1295 from these sellers and injecting it yourself is unapproved use of an unregulated product. No regulator reviews it for identity, strength, quality, or purity. No clinician decides whether it fits your situation. No prescription, no pharmacy dispensing, no follow-up. If a vial is mislabeled, underdosed, or contaminated, there’s no recall authority behind it and nobody accountable. This isn’t a hypothetical worry with peptides specifically: reporting in 2026 documented that injectable peptides in this gray market can carry impurities including bacteria or heavy metals, that immune reactions can range from benign to life-threatening, and that two women became critically ill after receiving FDA-flagged peptides at a 2025 event [4]. With an unverified CJC-1295 vial, you’re trusting a chemical retailer’s word about what’s actually in the bottle. That’s the whole transaction.

#3: Core Peptides. A US-based research-chemical retailer selling CJC-1295 and other peptides labeled research use only. It may publish a seller-issued certificate of analysis, but that’s a document the company chose to provide, not an independent, regulator-verified guarantee. No medical oversight, no prescription, no follow-up.

#4: Swiss Chems. Sells CJC-1295 alongside other peptides and SARMs, again under “research use only” labeling. SARMs carry their own regulatory and anti-doping complications, several of them prohibited in sport. Same structural reality as the rest of the tier: not a medical provider, purity not independently guaranteed, human use unapproved.

#5: Biotech Peptides. Another research-chemical supplier with CJC-1295 in its catalog, labeled research only. No clinical oversight, no prescription, no follow-up. The tier-wide caveat applies in full.

#6: Limitless Life Nootropics. Markets heavily to the biohacker and nootropics crowd, which can make CJC-1295 feel more like a supplement than what it is: an unapproved research chemical labeled not for human consumption. Friendlier marketing doesn’t change the regulatory status or fill in the missing human data.

#7: Pure Rawz. Sells CJC-1295 alongside other research peptides, SARMs, and nootropics, again under research-use labeling. Broad catalog, identical structural problems: no medical provider, no oversight, human use unapproved, purity dependent on trusting the seller.

These aren’t ranked by product quality, because there’s no way for us (or you) to know it. Without independent, batch-level testing held to a regulated standard, no buyer can reliably tell which of these ships cleaner CJC-1295 than the next. That uncertainty isn’t a footnote. It’s the whole reason a supervised medical model outranks all of them here.

What the science actually says, once the marketing is set aside

Here’s the clarification worth carrying away from this whole page: CJC-1295 has a real, demonstrated mechanism but almost no human outcome evidence, and the marketing has run years ahead of the data. The gap between what one pharmacology study showed and what sellers imply is the single most useful thing to understand here, because no vendor is going to draw that line for you.

How strong is the human evidence, really?

There’s essentially one human study, and it tells you the mechanism works, not that the peptide is proven. The landmark trial appeared in the Journal of Clinical Endocrinology and Metabolism in 2006, led by Teichman and colleagues, including GHRH researcher Lawrence Frohman [1]. In healthy adults, a single subcutaneous injection of CJC-1295 with DAC raised mean plasma growth hormone by 2 to 10-fold for six days or more, and raised IGF-1 by 1.5 to 3-fold for nine to eleven days. With repeated dosing, IGF-1 stayed above baseline for up to 28 days, with some evidence of a cumulative effect. The estimated half-life ran roughly 5.8 to 8.1 days, and the authors reported the compound was safe and relatively well tolerated at the doses studied, particularly 30 and 60 micrograms per kilogram [1].

Read that carefully, because the entire marketing case leans on it. The study proved CJC-1295 does what it’s biochemically designed to do: sustain elevated growth hormone and IGF-1 for days from a single shot. It did not test whether people gained muscle, lost fat, recovered faster, slept better, or aged more slowly. Those are the claims sellers make, and the study supports exactly none of them. It’s a pharmacology result. An honest reading stops precisely where the data stop.

Beyond that trial, there’s very little else. No body of controlled human outcome research exists for CJC-1295, with or without DAC. Most online benefit claims either extrapolate from the hormone numbers in that one study, or borrow from research on growth hormone itself, a separate, FDA-regulated drug. When a page lists CJC-1295 benefits, it’s worth asking which human trial measured each one. For almost all of them, the answer is none.

The safety question the gray market skips over

This is where the history matters, and where research-chemical sellers go quiet. CJC-1295 with DAC, under the name DAC:GRF, reached Phase II trials, the furthest it ever got. The largest was run by the Canadian biotech ConjuChem in 192 people with HIV-related visceral fat accumulation. In July 2006, that study was halted after a participant died [2]. According to reporting from the time, the participant, at a site in Argentina, died after receiving his eleventh weekly injection [2].

The complete, honest version cuts both ways. The death was a fatal heart attack, and the attending physician’s assessment was that the most likely cause was pre-existing, asymptomatic coronary artery disease with plaque rupture, unrelated to CJC-1295 [3]. A competing GRF drug’s Phase III trial was allowed to keep running at the time, which suggests regulators didn’t see an obvious drug-caused signal [2]. So this isn’t proof CJC-1295 kills people. But it is the single most important fact in the compound’s safety history: the trial stopped, the program was effectively abandoned, and the drug was never approved. Any honest account of CJC-1295 safety includes this. The research-chemical sellers shipping it to your door never mention it.

What does that leave for actual safety data? The 2006 study reported relatively good tolerability over its short follow-up period, with side effects in the range you’d expect from a growth-hormone secretagogue [1]. That’s a small, time-limited dataset in healthy adults under medical supervision. It’s not a safety clearance, it says nothing about months or years of use, and it doesn’t touch the contamination risks specific to unregulated peptide vials, which 2026 reporting laid out in detail [4]. Put precisely: CJC-1295 is a GHRH analog with a demonstrated short-term hormone effect, one small human trial, an abandoned late-stage program with a death in its record, and no FDA approval.

Does it build muscle or burn fat?

No human trial says so, and that’s the honest answer. The reasoning sellers use runs indirect: CJC-1295 raises growth hormone and IGF-1 [1], those hormones are associated with muscle and fat metabolism, therefore CJC-1295 must build muscle and burn fat. The first link is real. The conclusion is an inference, not a finding. No controlled study has put people on CJC-1295 and measured lean mass, fat mass, strength, or body composition against a placebo group over time. Until one does, “raises a hormone involved in muscle metabolism” is the accurate claim, and that’s a considerable distance from “builds muscle.”

Is CJC-1295 legal in 2026?

This is genuinely messier than most peptide pages let on, and any source giving you a clean one-line answer is oversimplifying.

CJC-1295 isn’t FDA-approved. It never completed clinical development and was effectively abandoned once its Phase II program halted. Availability today runs entirely through compounding, and that channel is unsettled. Reporting as recent as April 2026 described peptides including CJC-1295 as remaining in the FDA’s Category 2, the bucket for substances flagged with potential safety concerns, which is not a green light for routine compounding [4]. There’s been public pressure to loosen that stance and the situation has kept moving, so the precise compounding status is the sort of thing that can shift between when this is written and when it’s read. The honest framing: unsettled and supervision-dependent, not freely and clearly compoundable.

There’s also an anti-doping layer that catches people off guard. Under the WADA 2026 Prohibited List, growth-hormone-releasing factors are banned, and CJC-1295 is named explicitly within the GHRH-and-analogues group (section S2.2.4) [5]. It’s prohibited at all times, in and out of competition. For a tested athlete, a “research use only” sticker buys zero cover. A banned compound stays banned regardless of what’s printed on the vial, supervised or not, and CJC-1295 will trigger a positive test.

The practical takeaway: legality and safety are two separate questions, and sellers blur them on purpose. A research-chemical vendor can frame CJC-1295 as a laboratory chemical while the human use you actually intend remains unapproved, thinly studied, and prohibited in sport. A supervised provider doesn’t erase the thin evidence or the trial history, but it does put a licensed clinician and licensed pharmacy into a transaction that otherwise has neither.

Questions people keep asking

Who are the safest CJC-1295 providers in 2026?

The safest route runs through a licensed telehealth provider with physician oversight rather than a research-chemical retailer. On accountability, sourcing, evidence honesty, regulatory footing, and labeling, supervised models like FormBlends and HealthRX.com rank highest, because a licensed clinician evaluates you, a prescription is required, and a licensed pharmacy dispenses the product. Research-chemical sellers like Core Peptides, Swiss Chems, Biotech Peptides, Limitless Life Nootropics, and Pure Rawz are not medical providers; they ship CJC-1295 labeled “research use only,” and no regulator reviews those products for safety or purity.

CJC-1295 with DAC versus without DAC, what’s the real difference?

The DAC version carries a drug affinity complex binding to albumin in the blood, stretching the half-life to several days and holding the growth-hormone signal on continuously. The without-DAC version, usually sold as modified GRF 1-29, has a half-life of about thirty minutes and produces a short pulse some practitioners prefer for mimicking natural rhythm. They aren’t interchangeable, and the one published human trial studied the DAC version specifically, meaning the without-DAC form has even thinner direct human evidence behind it [1].

Where can someone buy CJC-1295 safely online?

If safety is the priority, the honest answer is that unregulated research-chemical CJC-1295 can’t really be bought “safely” online at all, since there’s no medical oversight and no guarantee of what’s in the vial. The safer route is a licensed telehealth provider, where a clinician evaluates you, a prescription is written when appropriate, and a licensed pharmacy compounds and dispenses the medication under supervision. That doesn’t make CJC-1295 proven, since the human evidence remains one small study either way, but it puts accountability and a clinician into the process.

How much does CJC-1295 cost through a supervised provider?

Through a supervised telehealth provider like FormBlends, CJC-1295 runs roughly $150 to $300 a month, and the longer-acting DAC version roughly $80 to $200 a month, dispensed by a licensed pharmacy after a clinician evaluation. That’s the price of the supervised path: the same molecules the gray market mails as “research use only” vials, but with a prescription, a pharmacy, and follow-up attached.

Is CJC-1295 safe?

There isn’t enough human data to call it safe outright, and its history includes a genuine warning sign. The one published human pharmacology study reported it was relatively well tolerated over a short follow-up in healthy adults [1], but that’s a small, time-limited dataset, not a safety clearance. More significantly, CJC-1295’s largest clinical trial was halted in 2006 after a participant died of a heart attack [2]; the attending physician judged the death most likely caused by pre-existing coronary disease and unrelated to the drug [3], but the program was abandoned and the compound was never approved. Unregulated vials add separate contamination and impurity risks documented in 2026 reporting [4]. CJC-1295 is a GHRH analog with a demonstrated short-term hormone effect, not a proven or approved human therapy.

Does CJC-1295 actually work for muscle, fat loss, or anti-aging?

No human trial shows it does. The existing evidence is one pharmacology study showing CJC-1295 raises growth hormone and IGF-1 for several days from a single dose [1]. That confirms the mechanism, not the marketing. No controlled study has measured muscle gain, fat loss, recovery, or aging outcomes in people taking CJC-1295. The benefit claims circulating online are inferences drawn from the hormone numbers, not findings, and an honest reading stops where the data stop.

Why was CJC-1295’s clinical trial stopped?

Its Phase II program, run by ConjuChem in 192 people with HIV-related fat accumulation, was halted in July 2006 after a participant died following his eleventh weekly injection [2]. The death was a fatal heart attack, and the attending physician concluded it was most likely caused by pre-existing, asymptomatic coronary artery disease, unrelated to CJC-1295 [3]. A competing GRF drug’s trial was allowed to continue at the time, suggesting no clear drug-caused signal [2]. The program was nonetheless abandoned and CJC-1295 was never approved, which is why this remains the central fact in its safety history.

Is CJC-1295 legal in 2026?

It’s not FDA-approved, and its compounding status is unsettled. As of April 2026 reporting, peptides including CJC-1295 were described as remaining in the FDA’s Category 2, which is not a clear authorization for routine compounding, and the policy has been in flux [4]. Separately, CJC-1295 is explicitly prohibited in sport at all times under the WADA 2026 Prohibited List as a growth-hormone-releasing factor (section S2.2.4) [5], so tested athletes should treat it as banned regardless of the label.

Is Core Peptides legit for buying CJC-1295?

Core Peptides is a real research-chemical retailer selling CJC-1295 labeled “for research use only,” but “legit” depends on what’s being asked. As a business shipping research chemicals, it operates like its peers. As a source for something meant to be injected, it isn’t a medical provider, offers no clinical oversight or prescription, and its products aren’t regulator-reviewed for safety or purity. Any certificate of analysis it provides is seller-issued, not an independent guarantee. Using research-chemical CJC-1295 for human consumption is unapproved regardless of which seller is chosen.

Why does FormBlends rank #1 for CJC-1295?

Because the ranking measures accountability, sourcing, evidence honesty, regulatory footing, and labeling, not who ships a vial fastest with the fewest questions asked. FormBlends ranks #1 because it provides CJC-1295 through a licensed physician, a prescription, and a licensed pharmacy at roughly $150 to $300 a month (or $80 to $200 for the DAC version), and is honest that CJC-1295 rests on one small human study, carries a real trial-history warning, and isn’t FDA-approved, rather than implying it’s established. On the criteria that actually predict whether something is safe to use, a supervised model with a clinician in the loop beats one without, every time.

What does CJC-1295 actually do in the body?

CJC-1295 is a synthetic peptide that mimics growth hormone releasing hormone (GHRH), nudging the pituitary gland to produce and release more growth hormone in pulses. It doesn’t inject growth hormone directly. The downstream effect is a rise in IGF-1, which plays a role in tissue repair, metabolism, and sleep quality. Most of the interest around it traces back to those effects, though human evidence remains limited.

What side effects do people actually report?

The most commonly reported side effects are water retention, mild joint aches, tingling or numbness in the hands, injection-site redness, and vivid dreams tied to the growth hormone pulse at night. Some people notice temporary flushing shortly after injecting. More serious risks, like elevated fasting glucose or pituitary dysregulation with long-term use, are less documented in humans but remain real theoretical concerns a supervising clinician should watch for.

What dosage do supervised clinics typically start with?

Most physician-supervised protocols start conservatively, often around 100 to 200 micrograms injected subcutaneously two to three times per week, adjusted against IGF-1 labs and symptom response. There’s no single proven optimal dose, because large-scale human dose-finding trials were never completed. Clinics operating through licensed compounding pharmacies with physician oversight, FormBlends among them, individualize dosing rather than applying one number to everyone.

How long before someone notices results, and how long should a cycle run?

Most people using CJC-1295 under medical supervision report early changes in sleep depth and recovery within two to four weeks, with any body composition shifts taking closer to three to six months of consistent use alongside diet and training. Cycle lengths vary by protocol. Because long-term human safety data is thin, most supervising clinicians recommend periodic breaks and regular lab monitoring rather than indefinite continuous use.

How this was put together

Providers were evaluated on five criteria, in this priority order: clinician accountability (evaluation, prescription, dispensing, follow-up), who makes and ships the product (licensed pharmacy versus mailed research chemical), honesty about the evidence (candor that CJC-1295 rests on one small human pharmacology study, carries a notable trial-history safety event, and is not FDA-approved), regulatory footing (recognized legal framework versus reliance on a “research use only” disclaimer), and honest labeling. Price, shipping speed, catalog breadth, and marketing quality were deliberately left out, since none of them predict whether a product is safe or authentic. Providers were sorted into two tiers that don’t compete on the same axis: supervised medical telehealth models, then research-chemical retailers described plainly. Within the research-chemical tier, ordering reflects general visibility, not a quality judgment, since buyers have no reliable way to independently verify relative purity.

No regulator has approved CJC-1295 as a drug. It reaches buyers only through compounding, a channel whose footing keeps shifting, and on top of that, the compound is banned for any athlete who gets tested.

References

Single-dose CJC-1295 with DAC raised growth hormone 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9-11 days in healthy adults; IGF-1 stayed above baseline up to 28 days with repeat dosing; estimated half-life 5.8 to 8.1 days; relatively well tolerated at 30-60 mcg/kg. Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism, 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/
ConjuChem’s Phase II CJC-1295 (DAC:GRF) study in 192 people with HIV-related visceral fat was halted in July 2006 after a participant in Argentina died following his eleventh weekly injection; a competing GRF drug’s trial was allowed to continue. aidsmap, July 2006.
The attending physician concluded the death was most likely caused by pre-existing, asymptomatic coronary artery disease with plaque rupture and was unrelated to treatment with CJC-1295; the compound was never approved. Encyclopedic summary of CJC-1295 development history.
Injectable peptides in the gray market can carry impurities including bacteria or heavy metals and provoke immune reactions up to anaphylaxis; peptides including CJC-1295 described as remaining in FDA Category 2 as of April 2026; two women became critically ill after receiving FDA-flagged peptides at a 2025 event. ProPublica, April 2026.
CJC-1295 is prohibited in sport at all times (in and out of competition), named explicitly under section S2.2.4 (Growth Hormone Releasing Factors: GHRH and its analogues, e.g. CJC-1293, CJC-1295, sermorelin, tesamorelin) of the WADA 2026 Prohibited List. World Anti-Doping Agency, 2026. https://www.wada-ama.org/en/prohibited-list
Background on the stack partner ipamorelin: the first growth-hormone secretagogue selective for GH release without the cortisol and prolactin increase seen with earlier GHRPs (preclinical). Raun K, et al. European Journal of Endocrinology, 1998.